Top Story Today
Novo Nordisk's Flagship Obesity Drug Just Lost to Zepbound on the Biggest Stage
CagriSema, Novo Nordisk's next-generation obesity combo, failed to prove it was even as good as Lilly's Zepbound in a head-to-head Phase 3 trial. Patients on Zepbound lost roughly 25.5% of their body weight versus 23% for CagriSema, and the confidence interval crossed the line into statistical inferiority. Deutsche Bank called the result "the worst case scenario." Analysts slashed CagriSema sales forecasts by 40 to 63%, and Novo's stock has now fallen about 50 to 60% from its 2024 peak. Lilly holds roughly 60% of U.S. injectable GLP-1 prescriptions and isn't slowing down.
Why it matters: This result removes the last plausible argument that Novo had a near-term answer to Lilly's efficacy lead, reshaping the multibillion-dollar GLP-1 obesity landscape and forcing Novo to pin its hopes on pipeline assets like amycretin that are years from market.
Read more →Clinical Wins and Regulatory Moves
Takeda's $4 Billion Psoriasis Bet Just Demolished the Competition
Takeda's psoriasis pill zasocitinib more than doubled Sotyktu's complete skin clearance rate in a direct head-to-head trial: 35% versus roughly 14%. The drug maintains round-the-clock target suppression compared to Sotyktu's much shorter duration. Takeda plans to file for FDA approval this fiscal year, vindicating a $4 billion acquisition that raised plenty of eyebrows in 2023.
Read more →A Rare Eye Cancer With Almost No Options Just Got a Real Treatment
IDEAYA's combo therapy cut disease progression risk by 58% in metastatic uveal melanoma patients who can't use the only approved targeted therapy. Tumor response rates hit 37% versus just 6% for standard care. IDEAYA's stock surged 21%, and the company plans an FDA filing in the second half of 2026.
Read more →Roche's Tecentriq Gets FDA Fast Track for Early-Stage Colon Cancer
The FDA granted Priority Review to Roche's Tecentriq for stage III colon cancer patients with a specific genetic signature, cutting relapse risk by 50% in the ATOMIC trial. No checkpoint immunotherapy is currently approved in this setting, giving Roche a wide-open competitive lane. Decision expected October 9.
Read more →Big Pharma Shakeups
Genentech Fired a 29-Year Scientific Legend. The Message Is Loud.
Genentech dismissed three VPs from its legendary gRED research unit, including Vishva Dixit, a National Academy member who spent 29 years mapping how cells die. Entire research departments are being shut down as Roche consolidates around cancer and immunology. Over 700 roles have been cut in 18 months, raising questions about whether biotech's most storied R&D culture can survive.
Read more →Novo's New CEO Lays Out a Comeback Plan. Wall Street Says: Prove It.
New CEO Mike Doustdar gave his first major interview, promising aggressive M&A and a laser focus on cardiometabolic disease. Novo has already spent billions acquiring Akero, with amycretin headed to Phase 3. But analyst sentiment remains bearish, and 2026 guidance calls for sales to drop 5 to 13%.
Read more →The FDA Just Declared War on Cheap Ozempic
The FDA launched a major crackdown on compounding pharmacies selling knockoff GLP-1 drugs, issuing 21 warning letters for quality violations and proposing rules to permanently shut down the mass-compounding pathway. Hims & Hers took the hardest hit: shares cratered roughly 75% from peak, and HHS referred the company to the Department of Justice.
Read more →Science and Early-Stage Bets
A $130M Startup Thinks CGRP Is Only Half the Migraine Answer
Slate Medicines launched with $130 million to target PACAP, a migraine trigger pathway that operates independently of the CGRP system current drugs block. About half of migraine patients don't get meaningful relief from CGRP therapies. The lead drug was licensed from China's DartsBio, with Phase 1 trials planned for mid-2026.
Read more →Lab-Grown Heart Cells Just Got Threaded Through a Catheter for the First Time
Japanese biotech Heartseed dosed its first patient with iPSC-derived heart muscle cells delivered via catheter, bypassing open-heart surgery entirely. The 70-something patient received 150 million cardiomyocytes across 15 injection sites and was discharged on schedule. It's the earliest proof point for a concept that could eventually reach millions of heart failure patients.
Read more →